Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Hypoparathyroidism future or investigational therapies
Introduction
Overview
Overview
In 1996, Winer and collegues demonstrated a reduction in calcium excretion in patients of hypoparathyroidism when treated with PTH 1-34 (teriparatide) when compared with treatment with calcitriol and calcium. PTH 1–34 (teriparatide) twice daily administered subcutaneoulsy provides a safe and effective alternative to calcitriol therapy and is capable of maintaining normocalcemia without hypercalciuria for at least 3 yr in patients with hypoparathyroidism. PTH 1-34 (teriparatide) has shown to improve the mental and physical health in hypoparathyroid patients.
Future or Investigational Therapies
Future or Investigational Therapies
Parathyroid hormone 1-34 (teriparatide)
- In 1996, Winer and collegues demonstrated a reduction in calcium excretion in patients of hypoparathyroidism when treated with PTH 1-34 (teriparatide) when compared with treatment with calcitriol and calcium.[1]
- Synthetic human was approved as a treatment for severe osteoporosis in 2002.
- PTH 1–34 (teriparatide) twice-daily shown to provide effective treatment of hypoparathyroidism and reduces the fluctuation in serum calcium levels at a lower total daily parathyroid hormone dose when compared to once daily regimen.[2]
- PTH 1–34 (teriparatide) twice daily administered subcutaneoulsy provides a safe and effective alternative to calcitriol therapy and is capable of maintaining normocalcemia without hypercalciuria for at least 3 yr in patients with hypoparathyroidism.[3]
- PTH 1–34 (teriparatide) is also safe and effective for treatment children with hypoparathyroidism when compared with conventional therapy.[4]
- PTH 1–34 (teriparatide) has shown to improve the mental and physical health in hypoparathyroid patients.[5]
References
References
- ↑ Winer KK, Yanovski JA, Cutler GB (1996). “Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism”. JAMA. 276 (8): 631–6. PMID 8773636.
- ↑ Winer KK, Yanovski JA, Sarani B, Cutler GB (1998). “A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism”. J. Clin. Endocrinol. Metab. 83 (10): 3480–6. doi:10.1210/jcem.83.10.5185. PMID 9768650.
- ↑ Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB (2003). “Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium”. J. Clin. Endocrinol. Metab. 88 (9): 4214–20. doi:10.1210/jc.2002-021736. PMID 12970289.
- ↑ Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB (2010). “Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium”. J. Clin. Endocrinol. Metab. 95 (6): 2680–8. doi:10.1210/jc.2009-2464. PMC 2902068. PMID 20392870.
- ↑ Santonati A, Palermo A, Maddaloni E, Bosco D, Spada A, Grimaldi F, Raggiunti B, Volpe R, Manfrini S, Vescini F (2015). “PTH(1-34) for Surgical Hypoparathyroidism: A Prospective, Open-Label Investigation of Efficacy and Quality of Life”. J. Clin. Endocrinol. Metab. 100 (9): 3590–7. doi:10.1210/jc.2015-1855. PMID 26196949.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]